Genie Energy Ltd. offers an alternative electricity supply model but shows volatile financial results and lacks consistent margin growth. Its EBITDA and margins have not kept pace with business expansion, with 2022 likely representing a cyclical peak. Due to the complexity and risk in the sector, the stock is considered less attractive compared to more stable utilities like Black Hills Corporation. Investors are advised to be cautious and conduct thorough research before investing in Genie Energy.
Genie Energy and its alternative electricity supply model provide context for the utilities sector. For readers following utilities stocks, here is Pluang's market snapshot as of Oct 14, 2026 19:42 WIB: out of 40 priced US utilities stocks, 22 rose and 14 fell. Notable movers include CenterPoint Energy Inc (CNP) at USD 39.59 with a 0.58% increase, Xcel Energy Inc (XEL) at USD 74.99 with a 0.47% increase, and FirstEnergy Corp. (FE) at USD 45.02 with a 0.42% decrease and 100% buy order activity on Pluang.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
